Pomegranate Juice (Ellagitannins)

Lowers blood pressure by a different route than beets, and the two plausibly stack.

Mechanisms, studies and evidence grades for each claim above.

Mechanism: ACE inhibition and eNOS, not nitrate

Pomegranate's characteristic compounds are ellagitannins — punicalagin, punicalin, pedunculagin, and gallagic acid — a class of hydrolysable tannins present in unusually high concentration in the fruit's peel and, in lower amounts, the arils and juice. They are large, poorly absorbed molecules, which matters enormously for how they work (see the urolithin section below).

The blood-pressure mechanism is angiotensin-converting enzyme inhibition — the same molecular target as the “-pril” drug class (lisinopril, ramipril). ACE converts angiotensin I to angiotensin II, a potent vasoconstrictor; inhibit it and vasoconstrictor tone falls. Early human work reported a 36% reduction in serum ACE activity after pomegranate juice consumption, alongside a 5% systolic fall. (Moderate for the enzyme effect; the study was small and the author's programme was industry-funded — see the provenance section) The specific inhibitory compounds have since been isolated independently, with pedunculagin, punicalin and gallagic acid showing IC₅₀ values around 0.9–1.8 µM, apparently by coordinating the catalytic zinc ion in ACE's active site. (Strong for the in-vitro biochemistry — this part is not in dispute and is independent of the funded clinical literature)

A second, additive route: punicalagin increases nitric oxide production by activating endothelial nitric oxide synthase (eNOS). Note the contrast with beet juice — beetroot bypasses eNOS by supplying nitrate that oral bacteria convert to nitrite and then NO, which is why it still works under hypoxia and acidosis when eNOS is impaired. Pomegranate instead works through eNOS, which means it depends on having reasonably functional endothelium to act on. (Animal–in-vitro for the eNOS mechanism)

The urolithin problem — why this works for some people and not others

Ellagitannins are barely absorbed intact. In the gut they hydrolyse to ellagic acid, which resident bacteria then convert into urolithins — smaller, absorbable metabolites that account for much of the systemic activity attributed to pomegranate. The conversion is not something human enzymes can perform.

People stratify into urolithin metabotypes: metabotype A produces urolithin A only; metabotype B produces urolithin B and isourolithin A as well; and metabotype 0 produces essentially none, lacking the necessary bacteria (Gordonibacter and Enterocloster species are among those implicated). Published non-producer estimates vary widely with population and method — figures anywhere from 10% to 40%+ appear in the literature, and the honest answer is that the number is not well pinned down. (Strong that metabotypes exist and vary; Contested on the actual population proportions)

This is the same structural feature as beet juice's dependence on oral nitrate-reducing bacteria, and it has the same consequence: the active molecule is manufactured by something living in you, so the dose-response is not a straightforward pharmacological one, and a meaningful share of trial participants may be getting little systemic exposure at all. It is a plausible contributor to the heterogeneity in these trials, and a reason to test the intervention on yourself rather than assume the average applies.

Human evidence

Blood pressure is where the evidence is strongest. A meta-analysis of 8 randomized controlled trials found systolic pressure fell by −4.96 mmHg (95% CI −7.67 to −2.25) and diastolic by −2.01 mmHg (−3.71 to −0.31). (Moderate) A later and larger analysis — 14 trials, 573 participants — found a near-identical systolic effect of −5.02 mmHg, which is reassuring on magnitude.

But that second analysis produced two findings that ought to change how the result is read, and which almost never survive into popular summaries:

• The effect was lost after about two months of continued intake. If that holds, pomegranate is an acute vasoactive food, not a treatment for chronic hypertension.
• The dose-response was non-monotonic — doses of ≤300 mL/day produced the largest systolic reduction, and larger doses did less for systolic pressure while retaining the diastolic effect.

Neither finding is necessarily real — both could be artefacts of having fewer and smaller long-duration and high-dose trials — but they are what the current data say, and the durability question is the one that matters most for anyone considering daily intake. (Contested — the durability finding rests on sparse long-duration data)

Beyond blood pressure the evidence thins quickly. There is a frequently-cited small study reporting reduced carotid intima-media thickness over three years, and a body of work on reduced LDL oxidation and paraoxonase activity — mechanistically coherent with the oxidation argument in Linoleic Acid & Metabolic Disease, since polyphenols that protect LDL from oxidative modification are acting on the same term. But these studies are small, largely from one research programme, and industry-funded. (Weak for any hard-outcome claim; no cardiovascular event trial exists)

The provenance problem

This entry discounts the pomegranate clinical literature more heavily than its raw volume would suggest, for a specific reason. POM Wonderful and its owners funded a very large share of it — reportedly more than $35 million across a hundred-plus studies at dozens of institutions — including much of the foundational work by Michael Aviram that established the ACE and LDL-oxidation findings. In 2010 the FTC charged the company with deceptive advertising over claims that its juice reduced the risk of heart disease, prostate cancer and erectile dysfunction; an administrative law judge upheld the complaint, the Commission affirmed, and the D.C. Circuit upheld that ruling in 2015. The FTC's specific finding was that the claims outran the evidence — for instance that a widely-promoted “30% plaque reduction” figure came from a single company-funded pilot study of 19 people.

Two things follow, and they point in opposite directions. The biochemistry is not affected — ACE inhibition by pomegranate ellagitannins has been independently characterised by groups with no commercial interest, and that work stands. The clinical literature, by contrast, was assembled largely by an interested party with a documented history of overstating it, and should be read with that discount applied. This is not a reason to dismiss pomegranate; it is a reason to weight the mechanism above the trials, which is the opposite of the usual ordering.

Practical use

• Form: whole arils beat juice. The ellagitannins come with fibre, the sugar arrives more slowly, and you avoid the concentrated fructose load that undercuts the point. Juice is what the trials used, not necessarily what makes sense.
• Dose: trials clustered around 150–300 mL of juice daily; the meta-analytic signal was strongest at ≤300 mL/day, so more is not better here. If using juice, unsweetened and not from concentrate.
• Timing: treat it as acute. Given the apparent loss of effect past two months, cycling — or using it situationally rather than daily — is at least as defensible as continuous intake, though no trial has tested a cycling protocol.
• Peel extracts: punicalagin concentration is far higher in peel than arils, which is why supplement extracts are usually peel-derived. That also concentrates the tannins, which can be gut-irritating at higher doses.
• Pair rather than substitute: if blood pressure is the goal, pomegranate and beet juice act on different nodes and are better thought of as complementary than as alternatives — though the combination is untested.
• The sugar caveat applies to every juice on this index — the same reasoning, and the same conditional answer, is worked through at length for orange juice, where the fructose argument is more developed.
• Don't expect it to carry the load: ~5 mmHg is real but small. The interventions with larger effects on the same endpoint are weight loss, aerobic training, and the sodium/potassium ratio — see the blood-pressure stack.

Citations for the specific figures above (the two BP meta-analyses, the ACE-activity and IC₅₀ values, the urolithin metabotype proportions, the FTC ruling) are given in numbered form in Statins, LDL & Cardiovascular Disease, refs 24–28, rather than duplicated here. The urolithin non-producer percentage is the weakest number on this page and is deliberately given as a wide range. The CIMT and LDL-oxidation claims have not been independently verified against the primary papers and are flagged as provisional.